United States Drug Patent 8,748,573: Linaclotide Formulation Scope, Patent Landscape, and Generic Entry Risk

US Patent No. 8,748,573 protects specific oral solid dosage forms of linaclotide for chronic constipation and constipation-predominant irritable bowel syndrome. Its commercial relevance is concentrated in formulation design rather than the basic linaclotide molecule or the broad therapeutic use.

The patent requires a defined combination of:

Linaclotide, identified by its 14-amino-acid sequence and three specified disulfide bonds.
A low microgram dose or a defined weight percentage.
Leucine at a specified ratio or concentration.
Calcium ion, preferably calcium chloride, at a specified ratio or concentration.
In several claims, a low concentration of a selected polymer.
In claims 9 and 10, a linaclotide hydrolysis product.

The patent is materially narrower than a basic composition-of-matter patent. A generic manufacturer could avoid literal infringement by changing the dosage form, excipient system, calcium or leucine levels, or product specifications, although the commercial product would still face other linaclotide patents, FDA requirements and potential doctrine-of-equivalents arguments.

What drug does US Patent 8,748,573 cover?

The covered active ingredient is linaclotide, a synthetic 14-amino-acid peptide and guanylate cyclase-C agonist marketed in the United States as Linzess.

The claimed peptide is:

Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr

The patent requires disulfide bonds between:

Disulfide bond	Required residues
First bond	Cys1-Cys6
Second bond	Cys2-Cys10
Third bond	Cys5-Cys13

This limitation excludes peptides with the same amino-acid sequence but a different disulfide-bonding pattern. It also excludes unrelated guanylate cyclase-C agonists, including peptide analogues with substituted residues, unless an asserted claim is interpreted under the doctrine of equivalents.

Linzess is approved for:

Irritable bowel syndrome with constipation in adults.
Chronic idiopathic constipation in adults.
Functional constipation in pediatric patients in specified age groups, under later FDA labeling expansions.

The claims in the '573 patent are directed to adult constipation-related treatment and require an oral, solid pharmaceutical dosage form. The patent does not cover every route of linaclotide administration or every pharmaceutical composition containing linaclotide.

What are the independent claims in US 8,748,573?

Claims 1 and 3 are the independent method claims supplied for analysis.

Claim 1: microgram dose and molar ratios

Claim 1 requires administration of an oral, solid dosage form containing:

Limitation	Required range
Linaclotide	100-300 micrograms
Leucine-to-linaclotide molar ratio	20:1 to 40:1
Calcium-to-linaclotide molar ratio	50:1 to 70:1
Indication	Chronic constipation or constipation-predominant IBS

The claim is conjunctive. A product must satisfy every limitation. A dosage form with 290 micrograms of linaclotide would not infringe claim 1 merely because it contains leucine and calcium. It must also fall within both ratio ranges.

Claim 3: weight-percent formulation window

Claim 3 uses a different formulation definition. It requires:

Component	Required amount by weight
Linaclotide	0.2%-0.4%
Leucine	0.5%-0.8%
Calcium salt	1.4%-1.65%

The percentages are measured relative to the total weight of the oral dosage form. Claim 3 does not state an absolute microgram dose. The same 290-microgram fill could fall inside or outside the claim depending on total dosage-form weight.

This creates two separate infringement pathways:

A product may satisfy claim 1 through absolute dose and molar ratios.
A product may satisfy claim 3 through weight percentages, even if the molar-ratio analysis differs.

A generic developer must therefore test both claim structures.

How do the dependent claims narrow the patent?

Claim	Added limitation	Scope effect
2	Polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropyl methylcellulose or mixture at 0.01%-2%	Narrows claim 1 to selected low-level polymers
4	Leucine at 0.6%-0.75%; calcium salt at 1.45%-1.65%	Narrows claim 3 toward a tighter formulation window
5	Leucine and calcium chloride	Narrows claim 3 to calcium chloride
6	Leucine and calcium chloride	Narrows claim 1 to calcium chloride
7	Selected polymer at 0.01%-2%	Narrows claim 3
8	Calcium-to-leucine molar ratio of at least 1.5:1	Narrows claim 1
9	Linaclotide hydrolysis product at 0.1%-4%	Narrows claim 1
10	Linaclotide hydrolysis product at 0.1%-4%	Narrows claim 3

Claims 5 and 6 contain wording stating that “the amino acid is leucine.” Because claims 1 and 3 already expressly require leucine, that language operates primarily as confirmation rather than a substantive narrowing limitation.

The polymer claims are formulation-specific. The listed polymers are commonly used pharmaceutical excipients, but the concentration range and combination with the linaclotide-leucine-calcium system create the relevant limitation.

What formulation technology does the '573 patent protect?

The patent protects a stabilizing excipient system for a low-dose oral solid linaclotide product. The technical focus is the interaction between linaclotide, leucine and calcium.

The formulation architecture has four principal elements:

Linaclotide as the active peptide.
Leucine as an amino-acid excipient.
Calcium ion, preferably supplied as calcium chloride.
Optional polymeric excipient at a low concentration.

Claims 9 and 10 are unusual because they expressly permit or require a specified concentration of a linaclotide hydrolysis product. This indicates that the invention is directed to a controlled stability profile rather than a formulation containing only chemically intact peptide.

The hydrolysis-product limitation creates a narrower but technically important claim. A finished product that contains a qualifying hydrolysis product within the 0.1%-4% range could fall within claims 9 or 10 even if the product sponsor does not intentionally add that material. The relevant issue would be whether the product contains the claimed hydrolysis product at the claimed concentration and whether the claim requires the product to be manufactured with, rather than merely contain, that impurity.

What is the likely claim construction of the key limitations?

“Oral, solid pharmaceutical dosage form”

This language generally covers capsules, tablets, sachets containing solid material, pellets and other solid oral presentations. It does not naturally cover an aqueous oral solution or a liquid suspension unless the accused product is treated as a solid dosage form before administration.

The Linzess capsule presentation is commercially relevant because it is an oral solid dosage form containing a low dose of linaclotide. The product’s label and FDA review materials identify the dosage form and inactive ingredients. [FDA, 2024]

“Between”

The ordinary reading of “between 100 micrograms and 300 micrograms,” and of the stated percentage and ratio ranges, generally includes the endpoints unless the specification or prosecution history indicates otherwise.

“Comprising”

The claims use “comprising,” an open transition. A formulation can contain additional excipients and still satisfy the claim. Adding a coating agent, diluent, lubricant or capsule component would not avoid infringement if all claimed ingredients and ranges remain present.

“Calcium salt”

Claims 5 and 6 specifically identify calcium chloride. Claims 1 and 3 are broader because they refer to calcium ion or a calcium salt. Calcium carbonate, calcium phosphate and other calcium sources could raise claim 1 or 3 issues if they supply the required calcium amount, but would not literally satisfy the calcium-chloride limitation in claims 5 or 6.

How can a generic manufacturer design around US 8,748,573?

A design-around should be evaluated against both independent claims and the dependent claims.

Design-around approach	Literal infringement risk
Use a liquid rather than solid oral dosage form	Reduces risk under the supplied claims
Use linaclotide outside 100-300 micrograms	Avoids claim 1, but not necessarily claim 3
Keep the dose but alter total dosage-form weight	May avoid claim 3 while claim 1 remains relevant
Use leucine outside the claimed molar and weight ranges	Reduces literal risk
Replace leucine with another excipient	Avoids the leucine limitations
Use calcium at a concentration outside the claimed ranges	Reduces risk under claims 1 and 3
Use a non-calcium counterion or no calcium salt	Avoids calcium-specific limitations
Use a polymer other than the four listed polymers	Avoids claims 2 and 7, but not claims 1 or 3
Keep the formulation but avoid the claimed hydrolysis-product range	May avoid claims 9 and 10
Use a modified linaclotide sequence or different disulfide pattern	Avoids the literal peptide limitation

The principal design-around risk is that changes to one parameter may move the product into another claim. For example, removing calcium chloride may defeat claims 5 and 6 but leave claim 1 potentially applicable if another calcium salt supplies the required calcium ratio.

When does US Patent 8,748,573 expire?

The patent issued on June 10, 2014. Public patent records identify a 2009 priority date for the underlying formulation work. The ordinary 20-year term therefore places the baseline expiration in 2029, subject to any applicable patent-term adjustment, terminal disclaimer or other term calculation recorded by the USPTO. [USPTO, 2014; USPTO, n.d.]

The patent is later-expiring than the principal linaclotide composition-of-matter patent. That difference matters commercially: expiration of the basic molecule patent does not necessarily eliminate formulation-patent risk.

What is the Orange Book status of US 8,748,573?

The FDA Orange Book is the controlling public source for patents listed against approved drug products, including patents covering drug substances, drug products and methods of use. [FDA, n.d.-a]

The relevant regulatory distinction is:

A listed formulation patent can support a Paragraph IV certification.
A generic applicant must address each listed patent associated with the reference product.
FDA approval timing may be affected by 30-month litigation stays, pediatric exclusivity, settlement terms and other statutory protections.
A patent claim that is not listed in the Orange Book can still be asserted in district court, but its procedural effect on ANDA approval may differ.

For Linzess, the commercial patent estate has included composition, formulation and method-of-use rights held or controlled by Ironwood Pharmaceuticals and its development or commercialization partners. The Orange Book listing should be reviewed by NDC and strength because listed patents and use codes can differ across approved presentations. [FDA, n.d.-a]

Which companies are challenging Linzess patent rights?

Generic linaclotide competition has involved ANDA applicants and patent litigation directed at the Linzess patent estate. Publicly reported challengers have included major generic manufacturers such as:

Amneal Pharmaceuticals.
Aurobindo Pharma.
Dr. Reddy's Laboratories.
Zydus Pharmaceuticals.
Apotex.
Torrent Pharmaceuticals.
Alembic Pharmaceuticals.

The relevant legal issue is not limited to the '573 patent. ANDA applicants typically challenge multiple listed patents through Paragraph IV certifications, with allegations involving invalidity, non-infringement or unenforceability. The patent owner may file infringement actions under 35 U.S.C. §271(e)(2), potentially triggering the statutory stay of FDA approval. [35 U.S.C. §§271, 355]

Settlement agreements may establish an agreed generic entry date before patent expiration. The commercial value of a settlement depends on the entry date, authorized-generic restrictions, product strengths, damages exposure and any covenant not to sue. The existence of a settlement does not itself invalidate the '573 patent or establish that the patent is non-infringed.

Is there biosimilar risk for linaclotide?

No conventional biosimilar pathway applies. Linaclotide is a synthetic peptide drug, not a biologic licensed under the Public Health Service Act.

Competitive products would ordinarily proceed through the FDA abbreviated new drug application pathway, provided the applicant can demonstrate pharmaceutical equivalence, bioequivalence and compliance with applicable patent certifications. FDA treatment of complex peptides can raise analytical and bioequivalence issues, but the legal framework is generally generic-drug competition rather than biosimilar substitution. [FDA, n.d.-b]

How strong is the patent estate for Linzess?

The '573 patent has moderate formulation-patent strength.

Strengths

It claims a specific active peptide and exact disulfide connectivity.
It combines multiple quantitative formulation limitations.
It covers both molar-ratio and weight-percentage formulations.
It includes calcium chloride embodiments.
It includes polymer and hydrolysis-product dependent claims.
The commercial product is an oral solid linaclotide dosage form, making product-to-claim comparison practical.

Weaknesses

The claims are narrow and highly numerical.
Small formulation changes may avoid literal infringement.
The peptide sequence and therapeutic use were known in the broader linaclotide development program.
Formulation claims may face obviousness challenges based on excipient screening, stability optimization and routine experimentation under 35 U.S.C. §103.
The hydrolysis-product claims may raise issues involving written description, enablement, measurement methodology and whether the claimed impurity is an intended formulation component.
Method claims require proof that the accused product is administered for the claimed indication.

The patent’s commercial strength depends heavily on whether the marketed product’s actual composition falls within the claimed ranges and whether later generic products use the same excipient architecture.

How does the '573 patent compare with the core linaclotide patents?

Patent category	Typical protection	Competitive significance
Composition of matter	Linaclotide sequence and related peptides	Broadest molecule-level protection
Therapeutic-use patents	Treatment of constipation or IBS-C	Relevant to labeled use and skinny-label strategy
Formulation patent, including '573	Leucine, calcium, polymer and stability parameters	Narrower but directly relevant to capsule products
Manufacturing patents	Peptide synthesis, oxidation and purification	Can create supply-chain and process barriers
Regulatory exclusivity	New-drug, pediatric or other FDA exclusivity	Controls approval timing independently of patent validity

The '573 patent should be assessed as one layer of a multi-patent estate. A generic applicant that avoids the '573 formulation claims may still face core composition, method-of-use, manufacturing or other formulation patents.

What generic launch scenarios exist?

Three scenarios are commercially plausible:

Early negotiated entry. A settlement permits launch before the baseline 2029 expiration date, subject to agreed conditions.
Paragraph IV litigation. The generic applicant litigates invalidity or non-infringement and seeks approval after a favorable judgment or settlement.
Post-expiration entry. The generic launches after all blocking patents and applicable regulatory exclusivities expire.

The most important diligence points are the actual Orange Book patent list, the ANDA certifications, use-code scope, district-court docket, settlement terms and the approved generic’s final formulation. A formulation that differs from Linzess may reduce '573 exposure while creating separate bioequivalence and manufacturing costs.

Key Takeaways

US Patent 8,748,573 is a formulation and treatment patent for oral solid linaclotide products.
Claim 1 requires 100-300 micrograms of linaclotide, leucine at a 20:1-40:1 molar ratio and calcium at a 50:1-70:1 molar ratio.
Claim 3 independently protects a formulation containing 0.2%-0.4% linaclotide, 0.5%-0.8% leucine and 1.4%-1.65% calcium salt.
Calcium chloride, selected polymers and linaclotide hydrolysis products are covered by dependent claims.
The patent’s baseline term reaches 2029 based on the identified 2009 priority date, subject to the USPTO’s recorded term calculation.
It is narrower than the core linaclotide composition patent but directly relevant to generic oral solid products.
Linaclotide competition proceeds through the generic-drug pathway, not the biosimilar pathway.
A credible design-around must evaluate both the molar-ratio claims and the weight-percentage claims.

FAQs About US Patent 8,748,573 and Linaclotide

Does US 8,748,573 cover all Linzess capsules?

No. It covers only products and administration methods satisfying the specific peptide, dosage-form, leucine, calcium and, where applicable, polymer or hydrolysis-product limitations.

Can a generic use 290 micrograms of linaclotide without infringing the patent?

Yes, potentially. The 290-microgram dose alone does not establish infringement. The generic must also be evaluated against the claimed molar ratios, weight percentages and other formulation limitations.

Does using calcium chloride automatically infringe US 8,748,573?

No. Calcium chloride is only one limitation in dependent claims 5 and 6. The product must also satisfy the incorporated limitations of claim 1 or claim 3.

Are linaclotide impurities relevant to patent infringement?

They may be. Claims 9 and 10 expressly recite a linaclotide hydrolysis product at 0.1%-4%. Analytical methods, impurity identity and concentration calculations would be central to any infringement analysis.

Is a generic linaclotide product a biosimilar?

No. A generic linaclotide product would generally be reviewed through the ANDA pathway, subject to pharmaceutical equivalence, bioequivalence and patent-certification requirements.

References

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application pathway. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
U.S. Food and Drug Administration. (2024). Linzess (linaclotide) prescribing information. https://www.accessdata.fda.gov/
U.S. Patent and Trademark Office. (2014). US Patent No. 8,748,573. https://patents.google.com/patent/US8748573
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/patents/laws/patent-term-adjustment
United States Code. (2024). 35 U.S.C. §§ 103, 271(e)(2), and 355. https://uscode.house.gov/

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	No	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	073075	⤷ Start Trial
Argentina	118601	⤷ Start Trial
Australia	2009282446	⤷ Start Trial
Brazil	PI0917807	⤷ Start Trial
Canada	2732892	⤷ Start Trial
Canada	2770077	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,748,573

Which drugs does patent 8,748,573 protect, and when does it expire?

Summary for Patent: 8,748,573